Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
In development
Reference number: GID-TA10752
Expected publication date:
Please note that following an update received from the company this appraisal is still to be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available during second half 2023.